Literature DB >> 18789525

Receptor mutation is not a common mechanism of naturally occurring glucocorticoid resistance in leukaemia cell lines.

Alex H Beesley1, Renae E Weller, Saranga Senanayake, Mathew Welch, Ursula R Kees.   

Abstract

Glucocorticoids (GCs) are among the most important drugs for the treatment of acute lymphoblastic leukaemia (ALL). Cell lines cultured in high GC concentrations typically contain mutated glucocorticoid receptor (GR), something that is rarely found in primary ALL specimens. We studied naturally occurring mechanisms of GC resistance and examined sensitivity to GC in 15 T-ALL cell lines grown without prior exposure to drugs. Resistance could not be attributed to mutations in GR or variations in levels of its expression. We conclude that this panel of cell lines provides a suitable in vitro model since it reflects GC resistance in primary ALL.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18789525     DOI: 10.1016/j.leukres.2008.08.007

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  10 in total

1.  Glucocorticoid receptor alpha isoform-selective regulation of antiapoptotic genes in osteosarcoma cells: a new mechanism for glucocorticoid resistance.

Authors:  Katherine L Gross; Robert H Oakley; Alyson B Scoltock; Christine M Jewell; John A Cidlowski
Journal:  Mol Endocrinol       Date:  2011-04-28

2.  MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid Malignancies.

Authors:  Ronit Vogt Sionov
Journal:  ISRN Hematol       Date:  2013-01-29

3.  Loss of TBL1XR1 disrupts glucocorticoid receptor recruitment to chromatin and results in glucocorticoid resistance in a B-lymphoblastic leukemia model.

Authors:  Courtney L Jones; Teena Bhatla; Roy Blum; Jinhua Wang; Steven W Paugh; Xin Wen; Wallace Bourgeois; Danielle S Bitterman; Elizabeth A Raetz; Debra J Morrison; David T Teachey; William E Evans; Michael J Garabedian; William L Carroll
Journal:  J Biol Chem       Date:  2014-07-25       Impact factor: 5.157

4.  Glucocorticoid-induced apoptosis of healthy and malignant lymphocytes.

Authors:  Lindsay K Smith; John A Cidlowski
Journal:  Prog Brain Res       Date:  2010       Impact factor: 2.453

5.  Combination of a selective activator of the glucocorticoid receptor Compound A with a proteasome inhibitor as a novel strategy for chemotherapy of hematologic malignancies.

Authors:  Ekaterina Lesovaya; Alexander Yemelyanov; Kirill Kirsanov; Alexander Popa; Gennady Belitsky; Marianna Yakubovskaya; Leo I Gordon; Steven T Rosen; Irina Budunova
Journal:  Cell Cycle       Date:  2012-12-19       Impact factor: 4.534

6.  Influence of wild-type MLL on glucocorticoid sensitivity and response to DNA-damage in pediatric acute lymphoblastic leukemia.

Authors:  Alex H Beesley; Janelle L Rampellini; Misty-Lee Palmer; Jasmin Y S Heng; Amy L Samuels; Martin J Firth; Jette Ford; Ursula R Kees
Journal:  Mol Cancer       Date:  2010-10-28       Impact factor: 27.401

7.  Down-regulation of 11β-hydroxysteroid dehydrogenase type 2 by bortezomib sensitizes Jurkat leukemia T cells against glucocorticoid-induced apoptosis.

Authors:  Yi Tao; Lu Gao; Xiaosong Wu; Hongmei Wang; Guang Yang; Fenghuang Zhan; Jumei Shi
Journal:  PLoS One       Date:  2013-06-24       Impact factor: 3.240

8.  Haploinsufficiency of NR3C1 drives glucocorticoid resistance in adult acute lymphoblastic leukemia cells by down-regulating the mitochondrial apoptosis axis, and is sensitive to Bcl-2 blockage.

Authors:  Haowen Xiao; Yingying Ding; Yang Gao; Li-Mengmeng Wang; Huafang Wang; Lijuan Ding; Xiaoqing Li; Xiaohong Yu; He Huang
Journal:  Cancer Cell Int       Date:  2019-08-23       Impact factor: 5.722

9.  Glucocorticoid resistance in T-lineage acute lymphoblastic leukaemia is associated with a proliferative metabolism.

Authors:  A H Beesley; M J Firth; J Ford; R E Weller; J R Freitas; K U Perera; U R Kees
Journal:  Br J Cancer       Date:  2009-05-12       Impact factor: 7.640

10.  Effect of cAMP signaling on expression of glucocorticoid receptor, Bim and Bad in glucocorticoid-sensitive and resistant leukemic and multiple myeloma cells.

Authors:  Hongli Dong; Michael E Carlton; Adam Lerner; Paul M Epstein
Journal:  Front Pharmacol       Date:  2015-10-13       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.